Top

Published in:

01-12-2021 | Probiotics | Commentary

Interplay between severities of COVID-19 and the gut microbiome: implications of bacterial co-infections?

Authors: Jyoti Chhibber-Goel, Sreehari Gopinathan, Amit Sharma

Published in: Gut Pathogens | Issue 1/2021

Abstract

COVID-19 is an acute respiratory distress syndrome and is often accompanied by gastrointestinal symptoms. The SARS-CoV-2 has been traced not only in nasopharyngeal and mid-nasal swabs but also in stool and rectal swabs of COVID-19 patients. The gut microbiota is important for an effective immune response as it ensures that unfavorable immune reactions in lungs and other vital organs are regulated. The human gut-lung microbiota interplay provides a framework for therapies in the treatment and management of several pulmonary diseases and infections. Here, we have collated data from COVID-19 studies, which suggest that bacterial co-infections as well as the gut-lung cross talk may be important players in COVID-19 disease prognosis. Our analyses suggests a role of gut microbiome in pathogen infections as well as in an array of excessive immune reactions during and post COVID-19 infection recovery period.

Li W, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–4.CrossRefPubMedPubMedCentral

Hernández Prada JA, et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension. 2008;51:1312–7.CrossRefPubMed

Kuba K, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875–9.CrossRefPubMedPubMedCentral

Crackower MA, Sarao R, Oliveira-dos-Santos AJ, Da Costa J, Zhang L. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417(6891):822–8.CrossRefPubMed

Wysocki J, Ye M, Rodriguez E, González-Pacheco FR, Barrios C, Evora K, Schuster M, Loibner H, Brosnihan KB, Ferrario CM, Penninger JM, Batlle D. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension. 2010;55(1):90–8.CrossRefPubMed

Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, Zhou J, Loibner H, Janzek E, Schuster M, Penninger JM, Herzenberg AM, Kassiri Z, Scholey JW. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes. 2010;59(2):529–38.CrossRefPubMed

Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112–6.CrossRefPubMedPubMedCentral

Tan ND, Qiu Y, Xing XB, Ghosh S, Chen MH, Mao R. Associations between angiotensin converting enzyme inhibitors and angiotensin II receptor blocker use, gastrointestinal symptoms, and mortality among patients with COVID-19. Gastroenterology. 2020. https://doi.org/10.1053/j.gastro.2020.05.034.CrossRefPubMedPubMedCentral

Anderson G. Psychological Stress and Covid-19: interactions with gut microbiome and circadian rhythm in driving symptom severity. 2020

10.

Vuille-dit-Bille RN, Liechty KW, Verrey F, Guglielmetti LC. SARS-CoV-2 receptor ACE2 gene expression in small intestine correlates with age. Amino Acids. 2020;52(6–7):1063–5.CrossRefPubMed

11.

Yang T, Chakraborty S, Saha P, Mell B, Cheng X, Yeo JY, et al. Gnotobiotic rats reveal that gut microbiota regulates colonic mRNA of Ace2 the receptor for SARS-CoV-2 infectivity. Hypertension. 2020;76:E1-3.CrossRefPubMed

12.

Xu Y, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med. 2020;26:1–4.CrossRef

13.

Wölfel R, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465–9.CrossRefPubMed

14.

Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.CrossRefPubMedPubMedCentral

15.

Roncon L, Zuin M, Rigatelli G, Zuliani G. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. J Clin Virol. 2020;127:104354.CrossRefPubMedPubMedCentral

16.

Wang J. et al. ACE2 expression by colonic epithelial cells is associated with viral infection, immunity and energy metabolism. MedRxiv. 2020

17.

Gou W. et al. Gut microbiota may underlie the predisposition of healthy individuals to COVID-19. MedRxiv. 2020

18.

Hashimoto T, Perlot T, Rehman A, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature. 2012;487:477–81.CrossRefPubMedPubMedCentral

19.

Perlot T, Penninger JM. ACE2-from the renineangiotensin system to gut microbiota and malnutrition. Microbes Infect. 2020.

20.

Wang D, Hu B, Hu C. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus—infected pneumonia in Wuhan China. JAMA. 2020. https://doi.org/10.1001/jama.2020.1585.CrossRefPubMedPubMedCentral

21.

Wan Y, et al. Enteric involvement in hospitalised patients with COVID-19 outside Wuhan. Lancet Gastroenterol Hepatol. 2020;5:534–5.CrossRefPubMedPubMedCentral

22.

Durack J, Lynch SV. The gut microbiome: relationships with disease and opportunities for therapy. J Exp Med. 2018;216:20–40.CrossRefPubMed

23.

Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020;382:e102.CrossRefPubMed

24.

Zhou F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.CrossRefPubMedPubMedCentral

25.

Du RH, et al. Predictors of mortality for patients with COVID-19. Eur Respir J. 2020;55:2000524.CrossRefPubMedPubMedCentral

26.

Chunxi LI, Haiyue LIU, Yanxia LIN, Jianbing PAN, Jin SU. The gut microbiota and respiratory diseases: new evidence. J Immunol Res. 2020. https://doi.org/10.1155/2020/2340670.CrossRefPubMedPubMedCentral

27.

Enaud R, Prevel R, Ciarlo E, et al. The gut-lung axis in health and respiratory diseases: a place for inter-organ and inter-kingdom crosstalks. Front Cell Infect Microbiol. 2020;10:9.CrossRefPubMedPubMedCentral

28.

Ohnmacht C. Microbiota, regulatory T cell subsets, and allergic disorders. Allergo J Int. 2016;25:114–23.CrossRefPubMedPubMedCentral

29.

Luu M, Steinhoff U, Visekruna A. Functional heterogeneity of gut-resident regulatory T cells. Clin Transl Immunol. 2017;6:e156.CrossRef

30.

Scales BS, Dickson RP, Huffnagle GB. A tale of two sites: how inflammation can reshape the microbiomes of the gut and lungs. J Leukoc Biol. 2016;100:943–50.CrossRefPubMedPubMedCentral

31.

Wang H, Lian P, Niu X, et al. TLR4 deficiency reduces pulmonary resistance to Streptococcuspneumoniae in gut microbiota-disrupted mice. PLoS ONE. 2018. https://doi.org/10.1371/journal.pone.0209183.CrossRefPubMedPubMedCentral

32.

Chang CS, Kao CY. Current understanding of the gut microbiota shaping mechanisms. J Biomed Sci. 2019;26:59.CrossRefPubMedPubMedCentral

33.

Libertucci J, Young VB. The role of the microbiota in infectious diseases. Nat Microbiol. 2019;4(1):35–45. https://doi.org/10.1038/s41564-018-0278-4.CrossRefPubMed

34.

West CE, Renz H, Jenmalm MC, Kozyrskyj AL, Allen KJ, Vuillermin P, et al. The gut microbiota and inflammatory noncommunicable diseases: associations and potentials for gut microbiota therapies. J Allergy Clin Immunol. 2015;135(1):3–13.CrossRefPubMed

35.

Belkaid Y, Hand T. Role of the microbiota in immunity and inflammation. Cell. 2015;157(1):121–41.CrossRef

36.

Costela-ruiz VJ, Illescas-montes R, Puerta-puerta JM, Ruiz C, Melguizo-rodríguez L. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020. https://doi.org/10.1016/j.cytogfr.2020.06.001.CrossRefPubMedPubMedCentral

37.

Weaver LK, Minichino D, Biswas C, Chu N, Lee JJ, Bittinger K, et al. Microbiota-dependent signals are required to sustain TLR-mediated immune responses. JCI Insight. 2019;4(1):1–9.CrossRef

38.

Xu K, et al. Management of corona virus disease (COVID-19): the zhejiang experience. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49:0.

39.

de Moreno de LeBlanc A, del Carmen S, Zurita-Turk M, Santos Rocha C, van de Guchte M, Azevedo V, et al. Importance of IL-10 modulation by probiotic microorganisms in gastrointestinal inflammatory diseases. ISRN Gastroenterol. 2011;2011:1–11.CrossRef

40.

Dhar SK, Damodar S, Gujar S, Das M. IL-6 and IL-10 as predictors of disease severity COVID-19 patients: results from meta-analysis and regression. MedRxiv. 2020. https://doi.org/10.1101/2020.08.15.20175844.CrossRefPubMedPubMedCentral

41.

van der Lelie D, Taghavi S. COVID-19 and the gut microbiome: more than a gut feeling. mSystems. 2020;5:e00453-20.CrossRefPubMedPubMedCentral

42.

Yeoh YK, Zuo T, Lui GCY, Zhang F, Liu Q, Li AYL, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021. https://doi.org/10.1136/gutjnl-2020-323020.CrossRefPubMed

43.

Tang L, Gu S, Gong Y, Li B, Lu H, Li Q, et al. Clinical significance of the correlation between changes in the major intestinal bacteria species and COVID-19 severity. Engineering. 2020. https://doi.org/10.1016/j.eng.2020.05.013.CrossRefPubMed

44.

Khatiwada S, Subedi A. Lung microbiome and coronavirus disease 2019 (COVID-19): possible link and implications. Hum Microb J. 2020;17:100073.CrossRefPubMedPubMedCentral

45.

Zuo T, Zhang F, Lui GCY, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. 2020;159:944-55.e8.CrossRefPubMed

46.

Schmulson M, Ghoshal UC, Barbara G. Managing the inevitable surge of post-COVID-19 functional gastrointestinal disorders. Am J Gastroenterol. 2021;116(1):4–7.CrossRefPubMed

47.

Zuo T, Liu Q, Zhang F, et al. Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. Gut. 2020. https://doi.org/10.1136/gutjnl-2020-322294.CrossRefPubMed

48.

Kalinkovich A, Livshits G. A cross talk between dysbiosis and gut-associated immune system governs the development of inflammatory arthropathies. Semin Arthritis Rheum. 2019. https://doi.org/10.1016/j.semarthrit.2019.05.007.CrossRefPubMed

49.

Huang L, Wang T, Wu Q, Dong X, Shen F, Liu D. Analysis of microbiota in elderly patients with acute cerebral infarction. PeerJ. 2019. https://doi.org/10.7717/peerj.6928.CrossRefPubMedPubMedCentral

50.

Bandy A. Ringing bells: Morganellamorganii fights for recognition. Public Health. 2020;182:45–50. https://doi.org/10.1016/j.puhe.2020.01.016.CrossRefPubMed

51.

Venegas DP, De La Fuente MK, Landskron G, González MJ, Quera R, Dijkstra G, et al. Short chain fatty acids (SCFAs) mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol. 2019;10:277.CrossRef

52.

Laszkowska M, Kim J, Faye AS, Joelson AM, Ingram M, Truong H, et al. Prevalence of Clostridioidesdifficile and other gastrointestinal pathogens in patients with COVID-19. Dig Dis Sci. 2021. https://doi.org/10.1007/s10620-020-06760-y.CrossRefPubMedPubMedCentral

53.

Food and agriculture organization and world health organization expert consultation. Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. Córdoba: Food and agriculture organization of the united nations and world health organization; 2001. ftp://ftp.fao.org/es/esn/food/probio_report_en.pdf. Accessed 8 Sept 2005.

54.

Guillemard E, Tanguy J, Flavigny A, de la Motte S, Schrezenmeir J. Effects of consumption of a fermented dairy product containing the probiotic Lactobacilluscasei DN-114 001 on common respiratory and gastrointestinal infections in shift workers in a randomized controlled trial. J Am Coll Nutr. 2010;29:455–68.CrossRefPubMed

55.

Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med. 2010;182:1058–64.CrossRefPubMedPubMedCentral

56.

Dhar D, Mohanty A. Gut microbiota and Covid-19-possible link and implications. Virus Res. 2020;285:198018.CrossRefPubMedPubMedCentral

57.

Gohil K, Samson R, Dastager S, Dharne M. Probiotics in the prophylaxis of COVID-19: something is better than nothing. 3 Biotech. 2020. https://doi.org/10.1007/s13205-020-02554-1.CrossRefPubMedPubMedCentral

58.

FAO/WHO. Joint FAO/WHO Working group report on drafting guidelines for the evaluation of probiotics in food. London, Ontario, Canada. 2002. April 30 and May 1: 1–11

Title: Interplay between severities of COVID-19 and the gut microbiome: implications of bacterial co-infections?
Authors: Jyoti Chhibber-Goel
Sreehari Gopinathan
Amit Sharma
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Probiotics
SARS-CoV-2
COVID-19
Post-COVID Syndrome
Cytokines
Published in: Gut Pathogens / Issue 1/2021
Electronic ISSN: 1757-4749
DOI: https://doi.org/10.1186/s13099-021-00407-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Interplay between severities of COVID-19 and the gut microbiome: implications of bacterial co-infections?

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

The endemic Helicobacter pylori population in Southern Vietnam has both South East Asian and European origins

High genetic diversity in Campylobacter concisus isolates from patients with microscopic colitis

Effect of intestinal microecology on postnatal weight gain in very preterm infants in intensive care units

Insights about the epidemiology of Salmonella Typhimurium isolates from different sources in Brazil using comparative genomics

Characteristics of patients infected with Clostridioides difficile at a Saudi Tertiary Academic Medical Center and assessment of antibiotic duration

Comparative genomic characterization of multidrug-resistant Citrobacter spp. strains in Fennec fox imported to China

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page